TALS - Talaris spikes on addition to Nasdaq Biotech Index

Talaris Therapeutics (NASDAQ:TALS) shares have recovered from two consecutive days of losses after the company announced that it would be part of the NASDAQ Biotechnology Index, effective before the market open Monday. The NASDAQ Biotechnology Index tracks the performance of a group of biotechnology or pharmaceutical stocks listed on the NASDAQ Stock Market. It is a market-cap-weighted index ranked on a semi-annual basis. Launched in 1993, the NASDAQ Biotechnology Index forms the basis for NASDAQ Biotechnology Index Fund. Talaris Therapeutics (TALS), focused on stem cell-based therapies, went public in May for $150M in gross proceeds. Its lead asset FCR001 is undergoing a late-stage trial in the U.S. for living donor kidney transplant (LDKT) patients. The company shares have well underperformed the broader market, as shown in the graph below.

For further details see:

Talaris spikes on addition to Nasdaq Biotech Index